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Induced pluripotent stem cells (iPSCs) avoid many of the restrictions that hamper the 
application of human embryonic stem cells: limited availability of source material due 
to legal restrictions in some countries, immunogenic rejection and ethical concerns. 
Also, the donor’s clinical phenotype is often known when working with iPSCs. Therefore, 
iPSCs seem ideal to tackle the two biggest tasks of regenerative medicine: degener-
ative diseases with genetic cause (e.g., Duchenne’s muscular dystrophy) and organ 
replacement in age-related diseases (e.g., end-stage heart or renal failure), especially 
in combination with recently developed gene-editing tools. In the setting of autologous 
transplantation in elderly patients, donor age becomes a potentially relevant factor that 
needs to be assessed. Here, we review and critically discuss available data pertinent 
to the questions: How does donor age influence the reprogramming process and iPSC 
functionality? Would it even be possible to reprogram senescent somatic cells? How 
does donor age affect iPSC differentiation into specialised cells and their functionality? 
We also identify research needs, which might help resolve current unknowns. Until 
recently, most hallmarks of ageing were attributed to an accumulation of DNA damage 
over time, and it was thus expected that DNA damage from a somatic cell would accu-
mulate in iPSCs and the cells derived from them. In line with this, a decreased lifespan 
of cloned organisms compared with the donor was also observed in early cloning 
experiments. Therefore, it was questioned for a time whether iPSC derived from an old 
individual’s somatic cells would suffer from early senescence and, thus, may not be a 
viable option either for disease modelling nor future clinical applications. Instead, typical 
signs of cellular ageing are reverted in the process of iPSC reprogramming, and iPSCs 
from older donors do not show diminished differentiation potential nor do iPSC-derived 
cells from older donors suffer early senescence or show functional impairments when 
compared with those from younger donors. Thus, the data would suggest that donor 
age does not limit iPSC application for modelling genetic diseases nor regenerative 
therapies. However, open questions remain, e.g., regarding the potential tumourigenicity 
of iPSC-derived cells and the impact of epigenetic pattern retention.
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FiGURe 1 | Donor age may reduce reprogramming efficiency, but has not been found to affect induced pluripotent stem cell (iPSC) maintenance or differentiation 
capacity, with a possible exception of the accumulation of mutations in mitochondrial and nuclear DNA. The reprogramming process and iPSC culture impact 
markers of cellular senescence and likely ensure a selection of functionally healthier clones. With prolonged iPSC culture, however, the risk of karyotype changes 
and the accumulation of mutations might increase. The normal ageing process is re-initiated once stemness mechanisms, such as telomerase function, are reduced 
in mature cells differentiated from iPSC.
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iNTRODUCTiON
Average life expectancy in most Western countries is above 
80 years and still rising (1). This development poses enormous 
challenges to both society and health care (2), as elderly patients 
suffer more frequently from chronic and degenerative diseases, 
such as chronic heart failure or kidney failure (3). Induced 
pluripotent stem cells (iPSCs) might represent a source of cellular 
material for regenerative therapies in those conditions, thereby 
avoiding limitations that impede the usage of embryonic stem 
cells (ESCs), namely immunological problems, limited availabil-
ity of source material as well as legal and ethical concerns.
Thus, ever since the first description of iPSCs (4), hopes have 
been high for a quick translation of the technology into clinically 
applicable therapeutic strategies. This hope has increased since 
the advent of novel gene-editing tools such as CRISPR/Cas9 
technology (5).
Given the fact that the elderly are the patient group with the 
greatest potential benefit from iPSC-based regenerative therapies, 
questions regarding the impact of donor age on the functionality 
of iPSCs and their offspring have arisen. This review aims to give 
an overview of the current base of knowledge regarding those 
issues and identifies unanswered research questions to tackle in 
the future.
iPSC RePROGRAMMiNG—HOw DOeS iT 
wORK AND HOw DOeS DONOR AGe 
AFFeCT iT?
Cellular Reprogramming
Cellular reprogramming is achieved by overexpression of the four 
Yamanaka factors (Sox-2, Oct-3/4, Klf-4, and c-Myc) in somatic 
cells, originally done using retroviral vectors (4). Since then 
other methods that avoid DNA-alterations have been described, 
such as adenoviral vectors (6) or recombinant proteins (7). More 
recently, the Sendai virus, an RNA virus, has been introduced (8), 
which has advanced to be the most widely used tool for cellular 
reprogramming in recent years.
During the process of cellular reprogramming, many internal 
changes occur in the cell, e.g., telomerase reactivation, changes in 
methylation patterns and mitochondrial morphology, as well as 
a decrease in senescence markers, e.g., p21 (9–12). It is thought 
today that iPSCs can be propagated indefinitely. In accordance 
with this, they retain telomerase activity and a stem cell-like 
epigenome, their mitochondria appear immature and are less in 
number compared with somatic cells (13). However, it has been 
shown that iPSCs can gain DNA mutations as well as karyotype 
aberrations (14) (Figure 1). Although it should be noted that the 
BOX 2 | What makes the clock tick? Senescence markers.
• Telomere attrition: telomeres are nucleotide repeat caps at the end of 
each chromosome. With each cell division, telomere length shortens due 
to imperfect DNA replication but also other harmful influences on the cell, 
e.g., oxidative stress (68). This telomere shortening is also observed in 
ageing, meaning cells from older individuals have shorter telomeres than 
those of younger ones (69).
• Loss of mitochondrial function: another sign of cellular ageing is mito-
chondrial dysfunction which is believed to be mainly due to accumulated 
damage caused by oxidative stress caused by prolonged close proximity 
of the mitochondrial DNA to reactive oxygen species as well as less effi-
cient DNA repair mechanisms in mitochondria compared with the nucleus 
(70, 71).
• Genomic instability: during its lifespan, a cell is continuously exposed to 
DNA altering stimuli, e.g., ROS (72) or radiation (73), and although most 
damage is repaired quickly, DNA mutations accumulate over time. This is 
also due to a loss of DNA repair efficiency (58). Furthermore, DNA damage 
is also introduced by erroneous DNA replication (74) and chromosomal 
segregation (75, 76).
• Histone modifications/epigenetic changes: during a cell’s lifespan, not 
all genes need to be transcribed at any one time and inhibition of gene 
transcription is in part conveyed by DNA methylation (77). Patterns of epi-
genetic alterations can be attributed to different cellular characteristics, e.g., 
senescence-associated patterns (35) or age-associated patterns (56). This 
is of special importance in cellular reprogramming seeing as not all forms of 
epigenetic memory are influenced in kind during cellular reprogramming. It 
is in part this fact, which makes iPSCs such a valuable research tool; donor- 
specific epigenetic characteristics remain unchanged during cellular 
reprogramming (78) and more importantly stay unchanged in iPSC-derived 
somatic cells (9). Otherwise, a reliable disease modelling through iPSC-de-
rived would not be possible seeing as it has emerged over the years that 
not only genetic but also epigenetic characteristics can influence and cause 
disease (79).
BOX 1 | What’s in a word? Ageing versus senescence.
An early theory of ageing identified accumulated DNA damage as the sole 
culprit of this inevitable process (64). In the meantime, it has been understood 
that ageing most likely is a multifactorial process affecting cells on multiple 
levels (65). Recently, nine hallmarks of ageing have been described, these 
are telomere attrition, genomic instability, epigenetic alterations, mitochondrial 
dysfunction, cellular senescence, stem cell exhaustion, altered inter-cellular 
communication, deregulated nutrient-sensing, and loss of proteostasis (66); 
the first five being most relevant to iPSC technology. Thus, cellular senescence 
is only a part of ageing and describes the loss of a cell’s division capacity. 
Multiple internal and external stimuli can induce cellular senescence, e.g., 
DNA damage or telomere loss, many ultimately leading to an upregulation of 
cell-cycle inhibitors, such a p21 (67). Finally, ageing has been recognised as a 
multifactorial process involving a decrease in efficiency and function of multiple 
cellular maintenance mechanisms with cellular senescence being the most 
obvious sign in cell culture.
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incidence of chromosomal aberrations is not higher than in ESCs 
(15). Following cellular reprogramming, iPSCs can be differenti-
ated into somatic cells, e.g., endothelial cells, cardiomyocytes, 
or neurons. With the differentiation into somatic cells, the cel-
lular ageing process restarts, although iPSC-derived somatic cells 
exhibit longer telomeres, improved mitochondrial function, lower 
senescence markers, p21 and p16, than their parent somatic cell 
(10, 16). Definitions of senescence and aging, as well as typical 
markers of senescence are discussed in Boxes 1 and 2.
Each of these steps and the resulting cells could, in theory, be 
affected by the age of the donor in various ways (Figure 1).
effect of Donor Age on iPSC 
Reprogramming efficiency
Very low reprogramming efficiencies for somatic cells from old 
donors compared with young ones have been reported (17) as 
well as the retention of age-associated DNA methylation patterns 
(18). In mice, it has been shown multiple times that donor age 
influences reprogramming efficiency (19, 20). Still, even cells 
from centenarians have on several occasions successfully been 
reprogrammed to iPSCs (10, 21), proving that advanced donor 
age on its own poses no insurmountable obstacle to the process 
of cellular reprogramming. Furthermore, multiple strategies have 
been found to improve cellular reprogramming efficiency, such as 
targeting senescence effectors (22) or easing access to pluripotency 
genes through C/EBPα (23). Still, it should be kept in mind that 
in human cells, it is up to now impossible to separate the impact 
of the very variable genetic background in the human population 
from the effect of age on iPSC reprogramming efficiency (24). 
Due to this variation, any comparison of interindividual repro-
gramming efficiency based on donor characteristics, such as age, 
is inherently flawed.
Another factor of equal importance for reprogramming 
efficiency is the time somatic cells are cultured before iPSC 
derivation (25). Moreover, prolonged passaging of fibroblasts 
was accompanied by a decrease in reprogramming efficiency 
and an upregulation of p21, a marker of cellular senescence (25). 
Thus, special care should be taken to optimise culture conditions 
when reprogramming cells from elderly donors.
In addition, different treatments have been shown to improve 
reprogramming efficiency for senescent cells, e.g., adding Nanog 
and LIN28 to the classic four Yamanaka factors (10) or knock-
down of p21 (25). These techniques might be of special interest 
in donors of very advanced age where only a limited number 
of somatic cells for reprogramming can be collected. However, 
in most cases, the number of cells collected with a normally 
sized blood sample is more than adequate for deriving iPSCs 
(26). Furthermore, the addition of ZSCAN10, a pluripotency 
factor, has been demonstrated to normalise ROS scavenging by 
glutathione and DNA damage response in iPSCs from old donors, 
thereby improving their quality (27).
HALLMARKS OF AGeiNG—HOw ARe 
THeY AFFeCTeD BY DONOR AGe AND 
CeLLULAR RePROGRAMMiNG?
Telomere Length
Early cloned organisms showed a decreased lifespan in comparison 
to their non-cloned counterparts (28), and it was theorised that 
shorter telomere length might be one reason for this observation 
(29). Reports of early iPSC-derived cells’ premature senescence 
seemed to underscore the validity of this (17). Nevertheless, it 
has been demonstrated that during cellular reprogramming 
telomere length increases through reactivation of telomer-
ase, and that telomerase reactivation is even necessary for 
4Strässler et al. iPSC and Aging
Frontiers in Cardiovascular Medicine | www.frontiersin.org January 2018 | Volume 5 | Article 4
successful reprogramming of somatic cells into iPSCs (30, 31). 
Some researchers showed that telomere length does vary con-
siderably between different iPSC lines (11) but that even iPSCs 
derived from centenarians have telomere lengths comparable to 
ESCs (10). With iPSC-derived fibroblasts still showing longer 
telomere length than their parent somatic cells after multiple pas-
sages (32). This strongly suggests that regarding telomere length, 
donor age does not negatively influence iPSC nor their somatic 
offspring (Figure 1).
Mitochondrial Function
A hallmark of human ESCs is their more immature mitochon-
drial morphology, and indeed, iPSCs show a similar mitochon-
drial morphology suggesting that iPSCs are comparable to 
their embryonic counterparts (33). Global assessment of mito-
chondrial function and energy metabolism in iPSCs and ESCs 
further emphasises their similarities (13). This mitochondrial 
“de-ageing” also leads to an improved mitochondrial function in 
iPSC-derived cells (16). Recently, however, it has been reported 
that iPSCs from older individuals carry more mutations in mito-
chondrial DNA (34), indicating that further research into this 
subject is needed and no conclusion on the influence of donor 
age on mitochondrial function in iPSCs and iPSC-derived cells 
might be drawn at this time.
epigenetic Modifications
Unlike disease-specific epigenetic changes, age-associated histone 
modifications are reverted to a more embryonic-like state by the 
reprogramming process (35). Furthermore, prolonged cultivation 
of iPSCs leads to an even stronger rejuvenation, i.e., methylation 
patterns become increasingly similar to ESCs the longer the 
iPSCs remain in culture (36). Senescence-associated epigenetic 
patterns undergo a similar rejuvenation process during cellular 
reprogramming and iPSCs can be passaged multiple times in vitro 
without entering a senescent state (35). Furthermore, it has been 
shown that iPSCs from both young and old donors exhibit a nega-
tive calculated age (based on CpG site methylation patterns) but 
still iPSCs from young donors score in the lower negatives than 
those of old donors (18). A problem lies in the retention of tissue-
specific epigenetic alterations which in part could be caused by 
incomplete reprogramming and might be improved by vigorous 
quality testing and careful selection of iPSC colonies during 
reprogramming and passaging (37). Retention of tissue-specific 
epigenetic characteristics might prove a hindrance to iPSC differ-
entiation into specific types of somatic cells. This fact might explain 
the observed inter-cell line disparity in differentiation efficiency 
(38). Furthermore, it has been shown that endothelial-derived 
iPSCs can be differentiated more easily into endothelial cells 
than iPSCs derived from other tissues of the same individual (39). 
If this proves true, the tissue for sample collection could be cho-
sen according to the later therapeutic application to improve iPSC 
differentiation as well as iPSC-derived cell function, e.g., sample 
muscle tissue if the desired tissue for later clinical use is iPSC-
derived cardiac muscle. Further studies are needed to answer the 
question whether retention of tissue-specific DNA methylation 
patterns is due to incomplete reprogramming as opposed to a 
natural characteristic of iPSCs.
DNA Mutations
With the preservation of genetic information during cellular 
reprogramming, one possible problem in using somatic cells 
from older individuals is the higher frequency of genetic aber-
rations (40). In fact, gene-disrupting DNA mutations in iPSCs 
increase with donor age and have been associated with cel-
lular dysfunction and cancer (18). Another potential problem 
of iPSC technology is that some of the patients’ cells might 
undergo mutation during the reprogramming process itself 
(41). Repeated passaging of the iPSCs might be able to mitigate 
both of these problems regardless of the age of the donor, as 
it appears non-mutated iPSCs have a growth advantage (42) 
(Figure  1). However, the data have been contradictory in 
this regard with some researchers also reporting an increase 
in both genetic mutations (14) and karyotype aberrations 
(15) with prolonged time in culture. This certainly has to be 
further investigated before a large-scale clinical application of 
iPSC technology is possible. This issue was illustrated in 2015 
when the first trial with iPSC-derived retinal pigment epithelial 
autologous cell transplantation had to be halted due to one 
patient’s iPSC-derived cells harbouring oncogene mutations 
(43, 44). However, it also shows that adherence to a thorough 
quality assessment of iPSC-derived cells before the final clinical 
application can prevent potential harmful effects (the trial has 
since been resumed; UMIN-CTR number: UMIN000011929).
FUNCTiONALiTY AND AGeiNG OF iPSCs 
AND iPSC-DeRiveD CeLLS—HOw iS iT 
AFFeCTeD BY DONOR AGe?
Induced pluripotent stem cells have to fulfil several criteria: virtu-
ally indefinite propagation capacity, the ability to give rise to cells 
from all three germ layers, as well as teratoma formation. None of 
these criteria seem to be negatively affected by donor age. Indeed, 
it has been demonstrated that even iPSCs of centenarians can be 
passaged over 110 times, can give rise to cells of all three germ 
layers, and are able to form teratomata (10, 21).
With regard to iPSC-derived cell function, early publications 
stated that iPSC-derived somatic cells show early senescence 
when cultured in vitro (32). However, this has not been confirmed 
(45). On the contrary, multiple hallmarks of cellular ageing 
(e.g., telomere attrition, age- and senescence-associated DNA 
methylation patterns) are reversed after the introduction of the 
four Yamanaka factors into somatic cells, as has been discussed 
before (Figure 1).
In mice, it has been shown that iPSC-derived cell functions 
are not negatively affected by donor age. In one study, iPSCs 
from both old and young mice were differentiated into vascular 
progenitor cells and transplanted into a mouse model of hindlimb 
ischaemia. No difference in iPSC differentiation efficiency was 
observed. In addition, both groups injected with iPSC-derived 
vascular progenitor cells showed comparable, improved 
hindlimb revascularisation compared with non-treated animals 
(46). Another study showed that cardiac tissue of iPSC-derived 
chimeric mice, with iPSCs derived from the bone marrow of 
2- and 18-month-old mice, showed no difference in telomere 
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length or mitochondrial gene expression and no upregulation of 
p16 nor p53 was detected between both age groups (47).
In humans, too, donor age does not seem to negatively impact 
on iPSC-derived cell functionality. This was demonstrated 
by Chang et  al. who compared both iPSCs and iPSC-derived 
erythroid cell quality derived from cells of donors of variable 
age (embryonic, fetal liver mesenchymal stem cells, and adult 
fibroblasts) and found no difference between the age groups 
(48). Another study showed the same in iPSC-derived fibro-
blasts, where fibroblasts from both old and young women were 
reprogrammed to iPSCs and further differentiated into iPSC-
derived fibroblasts. Both groups of iPSCs expressed comparable 
levels of pluripotency (Nanog, Oct-4, Sox-2, hTERT, SSEA-4, 
Tra-1-60, and Tra-1-81), senescence (p21 and p53), as well as 
apoptosis markers (Bax). Donor age did not negatively impact 
iPSC-derived fibroblast mitotic nor senescence-associated 
β-galactosidase activity (49). Indeed, when high-quality iPSC 
clones were chosen for further differentiation, even iPSC-derived 
fibroblasts from a 96-year-old donor could be cultured for 62 
population doublings, signifying a 50% gain of proliferation 
capacity (10). Another study by Chang et al. showed that iPSC-
derived erythroid cells from adult donors produced fetal and 
not adult haemoglobin supporting cellular rejuvenation during 
the reprogramming process (50). Furthermore, in a single-case 
study, Prigione et al. demonstrated that iPSC obtained from an 
84-year-old woman were able to differentiate into all three germ 
layers in embryoid body formation assays (12). Still, it has to be 
kept in mind that available findings are derived from a very low 
number of iPSC lines and thus statistical as well as methodologi-
cal limitations apply. Systematic studies assessing the impact of 
donor age on iPSC differentiation capacity in a large number of 
lines all produced and maintained under the same conditions are 
necessary to provide a final answer on the effect of donor age on 
iPSC differentiation capacity.
CeLLULAR ReJUveNATiON DURiNG iPSC 
GeNeRATiON—iS iT A PROBLeM FOR 
MODeLLiNG OF LATe-ONSeT DiSeASeS?
induced Pluripotent Stem Cells
One of the current key applications of iPSC technology is disease 
modelling, seeing as cell replacement therapy usually necessitates 
additional gene therapy of iPSCs before the cells or tissue might 
be transplanted. Moreover, in sight of the fact that iPSC-derived 
tissues show signs of rejuvenation, modelling of late-onset ill-
nesses is particularly challenging (51). Nonetheless, multiple 
ways of circumventing this problem have been suggested recently. 
One way, for example, is to overexpress progerin, the protein 
causing Hutchinson–Gilford progeria syndrome (52); another is 
to shorten telomeres in the iPSC-derived cells (53). Both cause a 
phenotype similar to aged cells in iPSC-derived cells, enabling the 
modelling of late-onset diseases.
The initial difficulties in modelling late-onset diseases should 
be seen as another indication that iPSC-derived tissues are at least 
partly rejuvenated and harbour great potential for future clinical 
applications, especially in elderly patients.
Nuclear Transfer
When talking about potential clinical applications of iPSC-derived 
cells, nuclear transfer should also be taken into consideration. 
After the discovery of iPSCs, nuclear transfer has taken a back 
seat in the field of regenerative medicine in part due to its much 
lower reprogramming efficiency. However, there are distinct 
differences inherent in the reprogramming process that might 
make nuclear transfer-derived stem cells (NT-SCs) a superior 
therapeutic option for a select number of patients.
For instance, nuclear transfer leads to longer telomeres in 
derived stem cells (54) and seems to erase epigenetic memory 
better than cellular reprogramming, for NT-SCs are more similar 
in their DNA methylation patterns to ESCs than iPSCs (38). 
However, there is some contention on this point as contradic-
tory data have been published (55). Another important fact is 
that mitochondria in NT-SC derived tissues stem from the 
oocyte donor and not from the patient themselves. Thus, NT-SCs 
could help in the treatment of mitochondrial diseases, e.g., Leigh 
syndrome or mitochondrial myopathy.
However, production of NT-SCs is costlier and more time-
consuming compared with iPSC derivation. To obtain oocytes, 
female donors must undergo hormonal stimulation, which 
carries a considerable risk for adverse effects (e.g., deep venous 
thrombosis or pulmonary embolism), and the harvesting process, 
if relatively safe, is still an invasive procedure in a person who will 
gain no later treatment benefit. However, seeing as mitochondrial 
diseases tend to manifest in young patients, there seems to be 
no particular benefit in nuclear transfer technology for elderly 
patients at the moment.
CONCLUSiON
In an ageing society, regenerative therapies are of great scientific 
and clinical interest and hold significant potential therapeutic 
benefits. Not only could they further prolong life but they could 
also—and this may be even more important—significantly 
improve quality of life for elderly patients suffering from chronic 
diseases such as diabetes, chronic heart failure, chronic kidney 
failure, or even neurodegenerative diseases (e.g., Parkinson’s or 
Alzheimer’s disease). Regenerative therapies using iPSC-derived 
cells, tissues, or organs are an ideal option because they avoid 
ethical dilemmas, immunological rejection of transplanted tis-
sue, and other problems discussed earlier. However, before these 
clinical benefits can come to fruition, essential questions need to 
be answered.
Some regard the influence of donor age on iPSCs and iPSC-
derived cell function and quality, which have been answered to 
some extent above. In a nutshell, iPSCs appear rejuvenated on 
a global scale: their telomere length is increased, mitochondrial 
function is improved, and epigenetic patterns are comparable 
to ESCs (16, 31, 33, 56). This rejuvenation is also passed on to 
the iPSC-derived somatic cells (10). Nonetheless, mutations 
in nuclear and mitochondrial DNA acquired over the donor’s 
lifespan and during the reprogramming process might persist. 
It remains to be verified if careful clone selection during iPSC 
culture and rigorous quality control are enough to overcome this.
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As stated before, at the moment, it is not yet known how 
strongly the variable genetic background of individual donors 
affects the reprogramming process and the quality of resulting 
iPSCs. This certainly poses a significant obstacle to quantify-
ing the influence of donor age on the whole process of cellular 
reprogramming. To more precisely pinpoint the influence of 
donor age on iPSCs and iPSC-derived cell function, it would be 
prudent to use cells from the same individual collected at differ-
ent time points. For instance, it has become increasingly popular 
for parents to cryogenically preserve the umbilical cords of their 
children (57), many of which are grown up by now. Thus, it would 
be relatively easy to assess the impact donor age has on the above-
mentioned qualities in the same individual, thereby minimising 
the confounding influence of interindividual genetic differences. 
Another point of contention is the tissue most often chosen for 
cellular reprogramming, namely, skin. Over a human’s lifespan, 
our skin is exposed to all kinds of mutagenic influences, e.g. UV 
radiation (58, 59). This could influence reprogramming efficiency 
and later iPSC-derived cell quality much more than donor age 
itself. Also, other locations for taking tissue samples are to be 
assessed critically. For instance, Wen et al. used vaginal fibroblasts 
as source material, but they did not screen for human papilloma-
virus, a prevalent infection which is known to be mutagenic and 
could, thus, be of importance as well (49, 60). In addition, it has 
to be stated that the number of cell donors was exceedingly low, 
namely n = 1 per group (49), which hardly allows for a meaningful 
statistical analysis. Due to the significant time and effort needed 
for even one iPSC line, a low number of donors and cell lines is 
a general problem in almost all research articles on the topic of 
iPSCs. This combined with the lack of a standardised protocol 
for optimal iPSC derivation, culture and quality control makes 
any comparison between different publications very difficult if 
not impossible. Especially, since it has been shown that many 
factors influence the quality of iPSCs and iPSC-derived cells, 
such as time and cell type used for reprogramming, time in cul-
ture, or reprogramming modality (25, 61). Particularly with the 
increasing number of different tissues used for iPSC derivation 
(e.g., skin fibroblasts, PBMCs from blood, or cells isolated from 
urine), further studies into the preservation of tissue-specific 
DNA methylation patterns as well as the influence of sample tis-
sue on differentiation potential of iPSCs and quality are required.
Also, other important questions are still unanswered, such as 
potential tumourigenicity of iPSC-derived cells as exemplified 
by the halted trial using iPSC-derived retinal pigment epithelial 
cells in 2015 in Japan (43, 44). On the other hand, it also dem-
onstrated that quality control was able to prevent the implanta-
tion of substandard iPSC-derived cells. The question regarding 
tumourigenicity will most likely only be answered satisfactorily 
once the differentiation methods are further improved, iPSC-
derived cell-based therapies have made their way further into 
clinical practice, and patients receiving treatments have been 
observed for multiple years. In the meantime, animal stud-
ies could add valuable insights. For instance, in 2014, rhesus 
macaques were injected with undifferentiated iPSCs which lead 
to teratoma formation, whereas injection of iPSC-derived meso-
dermal stromal cells leads to bone formation without teratoma 
formation (62). Recently, first animal studies combining gene 
therapy with iPSC technology have been published with positive 
results. In one study, iPSCs were derived from β-thalassaemia 
patients, underwent gene therapy, and were then differentiated 
into haematopoietic stem cells. These haematopoietic stem cells 
were then injected into non-lethally irradiated mice. In turn, 
these mice then showed an improved haematopoiesis compared 
with those injected with non-treated iPSCs from the same 
patients and—maybe more importantly—no tumour growth was 
observed (63).
With regard to the impact of donor age on iPSCs and iPSC-
derived cell quality and function, most studies point to a cellular 
rejuvenation during cellular reprogramming which is transferred 
to iPSC offspring, and the usage of somatic cells of old donors for 
iPSC derivation seems unproblematic, provided culture condi-
tions are of a sufficient standard. On the contrary, iPSC-derived 
cells from old donors show improved functionality and, thus, 
seem ideal as a means of therapeutic interventions.
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